Paget's disease of bone
- 1 February 1997
- journal article
- review article
- Published by Oxford University Press (OUP)
- Vol. 73 (856) , 69-74
- https://doi.org/10.1136/pgmj.73.856.69
Abstract
Summary: Paget's disease of bone is a relatively common condition in the UK affecting up to 5% of the population over the age of 55 years with particularly high prevalence in the North West of England. The majority of those affected are asymptomatic. Its precise cause remains unknown, and until recently, choice of treatment of this sometimes painful and debilitating disease has been limited. In this article, we review various aspects of this disease, concentrating particularly on recent advances in our understanding of its aetiology and its treatment.Keywords
This publication has 54 references indexed in Scilit:
- The effects of intravenous alendronate in Paget's disease of boneJournal of Bone and Mineral Research, 1995
- Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's diseaseJournal of Bone and Mineral Research, 1995
- Effects of Intravenous Pamidronate Therapy on Paget’s Disease of BoneThe Lancet Healthy Longevity, 1994
- ClodronateDrugs, 1994
- Efficacy and tolerability of a new formulation of oral tiludronate (tablet) in the treatment of paget's disease of boneJournal of Bone and Mineral Research, 1994
- Osteomalacia after pamidronate for Paget's diseaseThe Lancet, 1994
- PamidronateDrugs, 1991
- Mithramycin treatment of pacet's disease of bone exploration of combined mithramycin-ehdp therapyArthritis & Rheumatism, 1980
- Effect of calcitonin treatment on deafness due to Paget's disease of bone.BMJ, 1977
- Letter: Diphosphonate therapy in deafness associated with Paget's disease.BMJ, 1975